Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01717859 · ClinicalTrials.gov registry record · Phase 4
Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 74
- Enrollment target
NCT01717859 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 74 participants.
The verdict
NCT01717859, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if a change in inflammation or baseline inflammation seen on the ultrasound is a good indicator of how rheumatoid arthritis patients respond to TCZ 4mg/kg and whether early prediction of dose escalation is possible by utilizing ultrasound inflammatory measures.
Interventions
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01717859
The ClinicalTrials.gov registry entry for NCT01717859 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tocilizumab is the first listed.
NCT01717859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01717859 about?
NCT01717859 is a clinical study titled "Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab". The purpose of this research study is to determine if a change in inflammation or baseline inflammation seen on the ultrasound is a good indicator of how rheumatoid arthritis patients respond to TCZ 4mg/kg and whether early prediction of dose escalation is possible by utilizing ultrasound inflammato...
What is the current status of trial NCT01717859?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 74 participants. The study started on 2014-09. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01717859?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT01717859?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.